In the same way how financial incentives fueled the opioid crisis in the U.S., the same concept can be used to give patients better treatment. Opioid use disorder (OUD) is a chronic, relapsing illness, associated with significantly increased rates of morbidity and mortality. Offering financial incentives to hospitals shows strong potential to drive swift system and practice changes to intervene in the opioid epidemic, Penn Medicine research finds.
Hospital emergency departments (EDs) not only care for patients with overdose and other complications from opioid use, but they also serve as vital touch points to engage patients into longer-term treatment. After an overdose, patients are at risk for repeat overdose and death.
Pennsylvania is the first to establish a voluntary incentive program to improve the rate at which patients with opioid use disorder receive follow-up treatment after emergency department care. Evaluations of the program show that financial incentives are effective in producing rapid treatment innovations for opioid use disorder.
In a study, researchers at the Perelman School of Medicine at the University of Pennsylvania found that Pennsylvania’s financial incentive policy encouraged hospitals to enact rapid system and practice changes to support treatment for opioid use disorder for patients visiting the ED.
The study, which was recently published in Psychiatric Services, evaluates the efficacy of the Opioid Hospital Quality Improvement Program (O-HQIP), which Pennsylvania pioneered in 2019. The program seeks to increase the rate of follow-up treatment for Medicaid patients within seven days of an ED encounter for opioid-related illness by offering financial compensation to hospitals who participated in the program.
“Policy makers have recognized that strengthening the linkage from the ED to treatment is an opportunity to combat the opioid epidemic,” said senior author Zachary Meisel, MD, MPH, MSHP, an associate professor of Emergency Medicine and director of the Center for Emergency Care Policy and Research at Penn. “Offering financial incentives provides momentum for efforts to improve treatment access for opioid use disorder.”
The program identified four distinct treatment pathways: initiation of buprenorphine treatment during the ED encounter; warm handoff to outpatient treatment; referral to treatment for pregnant patients; and inpatient initiation of methadone or buprenorphine treatment.
An initial incentive for participation was paid to hospitals in 2019 and was contingent on participation in all four pathways, with lesser payments for partial participation. In future years, hospitals can earn additional incentives for improvements in performance.
To evaluate the degree of the program’s success, researchers conducted 20 semistructured interviews with leaders from a diverse sample of hospitals and health systems across Pennsylvania. Study interviews revealed that the incentives oriented institutional priorities toward expanding opioid treatment access.
Hospitals were often on the cusp of change and responded to this nudge to prioritize opioid treatment access. However, the study also revealed that most hospitals–specifically, smaller or independent hospitals with lower volumes of patients with opioid use disorder–were unable to justify investing in these resources internally. Some hospitals noted resources as a barrier to participation, despite the incentive payments.
Finally, while initiating buprenorphine in the ED is proven to improve patients’ health outcomes and retention in treatment, many hospitals found implementing a pathway for buprenorphine difficult and time-consuming, and all partially participating hospitals chose to forgo this pathway.
“Future work is needed to determine the effectiveness in improving patient outcomes not only for this initiative in Pennsylvania, but also for emerging treatment methods and payment innovations in the care of patients with opioid use disorder,” said Jeanmarie Perrone, MD, Director of the Division of Medical Toxicology and Addiction Medicine Initiatives, and a professor of Emergency Medicine at Penn.
How The Opioid Crisis Started
In the late 90s, pharmaceutical companies reassured the medical community that patients would not become addicted to prescription opioid pain relievers. As a result, healthcare providers began to prescribe them at greater rates.
Fast forward to 2017, nearly 50,000 people in the United States have died from opioid-involved overdoses. That same year, an estimated 1.7 million people in the United States suffered from substance use disorders related to prescription opioid pain relievers. By then, it became clear that these medications could indeed be highly addictive.
Why This Study Matters
The misuse of and addiction to opioids is a serious national crisis that affects public health as well as social and economic welfare.
The CDC estimates that the total “economic burden” of prescription opioid misuse alone in the United States is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement.
The road to recovery is a long one. But with the right initiatives, we might just be able to reverse the opioid crisis. Research like the one from Pennsylvania will not only provide us with scientific solutions to address the current opioid crisis but it will also equip us with the knowledge and tools we need to protect ourselves from future drug crises.